Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ?10)
KEYTRUDA Is Now Approved Across Five indications for Three Different Types of Cancer in China and Is First Anti-PD-1 Therapy...






